Significant improvements in treatment outcomes for relapsed and refractory non-Hodgkin’s lymphoma at all stages have been observed due to advancements in stem cell transplantation techniques, new cytotoxic protocols, and the recent discovery and utilisation of targeted therapies, such as the bcl-2 inhibitor venetoclax and the PD-1 inhibitor pembrolizumab” for improved coherence [53]. Here, BCL2 is linked to non-Hodgkin lymphoma.